PTC Therapeutics Inc
PTCT
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.3B
Close$
$29.89
52.9% downside
Current Fair Value
52.9% downsideOvervalued by 52.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.30 Billion |
|---|---|
| Enterprise Value | $4.94 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $8.58 |
| Beta | 0.55 |
| Outstanding Shares | 83,006,808 |
Return
| Return on Equity | 23.21% |
|---|---|
| Return on Assets | -1.18% |
| Return on Invested Capital | 4.82% |
Valuation & Multiples
| P/E Ratio | -129.51 |
|---|---|
| PEG | 56.62 |
| Price to Sales | 5.29 |
| Price to Book Ratio | -31.73 |
| Enterprise Value to Revenue | 4.9 |
| Enterprise Value to EBIT | 41.35 |
| Enterprise Value to Net Income | -129 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | -4.22 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$0.22
Average shareholder expectationRevenue Estimate
$295.38 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$0.29
Average shareholder expectationRevenue Estimate
$303.94 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1532▼ 2.10% |
|---|---|
| Total Calls | 788,300▼ 1.45% |
| Total Puts | 120,800▼ 13.34% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 122.07%▲ 6.31% |
|---|---|
| Total Invested | $8.26B▲ 26.99% |
| Investors Holding | 392▲ 30.00% |
ESG Score
No data
About PTC Therapeutics Inc
CEO: Stuart Peltz